Literature DB >> 10717341

A model to estimate the probability of hepatitis B- and Haemophilus influenzae type b-vaccine uptake into national vaccination programs.

M A Miller1, W D Flanders.   

Abstract

Most countries have been slow to adopt new vaccines into national vaccination schedules, despite recommendations from global multi-lateral agencies. Characteristics of countries that have adopted hepatitis B (HB) vaccine were analysed and used to formulate a logistic regression model. The model was applied to country-specific data to predict HB and Haemophilus influenzae type b (Hib) vaccine uptake. The greatest predictors of HB uptake were coverage rates of other vaccines, vaccine cost relative to the economy, and perceived disease burden. The logistic regression model's probability estimate of vaccine uptake agreed well with observed data for HB and Hib, (c-statistic 85 and 82%, respectively). Application of this model to other antigens may aid in predicting potential national markets to better plan new vaccine supply and demand.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10717341     DOI: 10.1016/s0264-410x(99)00563-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Forecasting dengue vaccine demand in disease endemic and non-endemic countries.

Authors:  Ananda Amarasinghe; Ole Wichmann; Harold S Margolis; Richard T Mahoney
Journal:  Hum Vaccin       Date:  2010-09-01

2.  Introduction of pentavalent vaccine in Indonesia: a policy analysis.

Authors:  Panji F Hadisoemarto; Michael R Reich; Marcia C Castro
Journal:  Health Policy Plan       Date:  2016-04-23       Impact factor: 3.344

3.  Accelerating policy decisions to adopt haemophilus influenzae type B vaccine: a global, multivariable analysis.

Authors:  Jessica C Shearer; Meghan L Stack; Marcie R Richmond; Allyson P Bear; Rana A Hajjeh; David M Bishai
Journal:  PLoS Med       Date:  2010-03-16       Impact factor: 11.069

4.  Estimating the demand for a preventive HIV vaccine: why we need to do better. Reliable estimates would help in achieving several policy and advocacy objectives.

Authors:  Robert Hecht; Chutima Suraratdecha
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.